Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spectranetics starts Turbo elite post-marketing trial

This article was originally published in Clinica

Executive Summary

Colorado-based Spectranetics has begun a German trial of its Turbo elite laser catheters in combination with Turbo-Booster. The PATENT trial is a prospective registry of 100 patients to assess arterial patency as measured by duplex ultrasound at intervals up to 12 months after the procedure. It will also assess the device's safety. The Colorado Springs firm's Turbo elite line of laser catheters was approved by the FDA for the treatment of all stenoses and occlusions in the leg arteries in July.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049836

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel